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Recent phase III trial data clearly demonstrate that adjuvant therapy can reduce recurrence and increase survival after prostatec-
tomy for prostate cancer. There is great interest in being able to accurately predict who is at risk of failure to avoid treating those
who may not beneﬁt. The standard markers consisting of prostate speciﬁc antigen (PSA), Gleason score, and pathological stage
are not very speciﬁc, so there is an unmet need for other markers to aid in prognostic stratiﬁcation. Numerous studies have been
conducted with various markers and more recently gene signatures, but it is unclear whether any of them are really useful. We
conducted a comprehensive review of the literature to determine the current status of molecular markers in predicting outcome
after radical prostatectomy.
1.Introduction
Prostate speciﬁc antigen (PSA), stage (either clinical or
pathological), and Gleason score are ﬁrmly established as
prognostic indicators in prostate cancer. Individually and
collectively, they predict for failure after radiation and
surgery. The predictive value has been increased with more
detailed information such as the addition of the detailed
pathological ﬁndings of extraprostatic extension (EPE),
positive margins, seminal vesicle involvement, and lymph
node involvement. Various combinations of factors have
been combined into tables, formulas, neural networks, and
nomograms. While they are important tools in trying to
predict failure, they are limited by the predictive ability of
the factors themselves. For example, from a nomogram, a
patient with a Gleason 7 (3 + 4) cancer with extraprostatic
extension and positive margins, negative lymph nodes,
negative seminal vesicles, and preoperative PSA of 8.2ng/mL
is predicted to have a 10-year recurrence rate of 20% [1].
Telling a patient that he has a 1 out of 5 chance of failing
may or may not be reassuring. The absolute precision would
be able to tell a patient whether he will fail (100%) or not
(0%). The ultimate goal is to try to determine who will fail,
not who may fail. The only way to try to approach that goal
is with more precise markers than we currently have. One
area of major promise in this regard is the greater individual
cancer data that can be obtained from molecular markers.
We already have seen an example of the beneﬁt of a
marker in prostate cancer. The addition of the biological
marker PSA oﬀers more precise information over stage
and Gleason score alone. In breast cancer, the marker
Her 2-neu has been shown to be not only an important
prognostic marker, but also a target of therapy [2]. The
identiﬁcation of the protein associated with bcr-abl (break
point cluster region-Abelson proto-oncogene fusion) led to
a major treatment breakthrough in chronic myelogenous
leukemia (CML) [3]. Given these successes, interest has
been generated in discovering molecular markers that would
help with prostate cancer. Numerous markers have been
evaluated, but usually in small numbers and in diverse
patient populations. Also, they rarely are evaluated as to
whether they enhance the predictive ability of the standard2 Prostate Cancer
markers. The real test of a new maker (and the key to its
success) will be whether it enhances the predictive ability
of the prognostic triad of PSA, Gleason score, and stage
(with all of its various subclassiﬁcations). The purpose of
this evaluation is to determine whether any of these are
truly helpful in determining who will fail after radical
prostatectomy and whether we should consider adding them
to our standard armatorium for evaluation.
2.Materialsand Methods
A comprehensive Medline search was undertaken to identify
studies of molecular markers in prostate cancer. In each of
those studies, references were evaluated to try to capture all
the studies that evaluated markers in patients undergoing
radical prostatectomy.
Most studies had too few patients to have enough statis-
tical power to make meaningful prognostic statements. Also,
most studies were not speciﬁc for patients that underwent
surgery for their prostate cancer, but rather a mixture of
diﬀerent treatment modalities. While we reviewed all the
studies, we focused on those with radical prostatectomy
patients that were treated with curative intent. We also
focused on studies with more than 50 patients, with the
premise that lesser numbers were unlikely to have statistical
relevance. In addition, we hoped to focus on studies that
evaluated the investigated markers in conjunction with at
least one of the accepted predictive factors (PSA, Gleason
score, and stage).As it turned out,direct correlation with the
knownpredictivefactorswasnotverycommonlyperformed.
We searched for studies that show the possibility of
increasing the predictive ability and discuss whether any
appear to be able to help us better predict failure. We
were not so much interested in determining the mechanistic
underpinnings of cancer development and the eﬀect on
stage, rather whether markers could help predict the clinical
behavior of prostate cancer and help determine appropriate
intervention to try to cure more patients.
3.Resultsand Discussion
The literature was quite diverse, which makes interpretation
of results diﬃcult and direct comparisons impossible. As
per all retrospective studies, there is inherent variation
in the selection of patients. In addition, even for the
same markers, the determination of positive and nega-
tive often varied greatly. Many of them were determined
by semiquantitative immunohistochemical (IHC) staining
with large methodological and intraobserver variability.
Some investigators acknowledged that the staining level to
determine what was “positive” had to be manipulated to
have signiﬁcant results [4]. Many studies included patients
that received neoadjuvant androgen ablation or adjuvant
androgen ablationand/orradiation therapy. Whileexcluding
those patients eliminates some of the perceived higher-risk
patients, including patients that have additional treatments
known to alter failure is also problematic. Also, most of
the studies have very short followup, which makes any con-
clusions about failure tenuous at best. Many expressed
markers show a close association with known prognostic
factors and while they may be positive on univariate analysis,
they fall out on multivariate analysis. These issues are
inherent to retrospective studies, but they should be kept in
mind.
3.1. Ki-67. Ki-67 is one of the earliest markers and is
named for the original mouse antibody researched in Kiel
Germany, reacting in well number 67 [5]. It serves as a
proliferation marker that occurs only in dividing cells (not
G0). The original antibody required fresh tissue, but the
MIB-1 antibody can be used in formalin ﬁxed tissue. The
assessment of Ki-67 gives an estimate (index) of the portion
of cells actively proliferating.
Some studies report that Ki-67 is prognostic for failure
(Table 1). In a study of 70 radical prostatectomy patients,
50 were selected for further analysis [6]. With a median
followup of 63 months, 18% failed (PSA > 0.2ng/mL). The
specimens were evaluated for Ki-67 via IHC staining. On
univariate analysis of PSA, PSA doubling time, Ki-67%,
tumor volume, and Gleason score, only Ki-67% and PSA
were signiﬁcant prognostic factors. In another study [7],
137 patients underwent radical prostatectomy with a mean
followup of 5.4 years. The cohort included 25% lymph node
positive and 36% received adjuvant therapy with radiation
and/or androgen ablation. Ki-6 7w a ss c o r e da st h ep e rc e n t
of staining >5% (78 or 57% if the patients) or <5% (59 or
43% of the patients); the mean was 7.5%. From the graph,
for patients below the mean staining, 5-year recurrence free
survival was approximately 78% compared to 65% if above
the mean. Ki-67 was a signiﬁcant factor on multiparameter
analysis. The largest study evaluating Ki-67 was of 528
prostatectomy patients after exclusion of those that received
neoadjuvant and adjuvant androgen ablation and radiation
therapy [8]. With a median followup of 46 months, 101
(19%) failed for a 5-year disease-free (PSA < 0.2ng/mL)
rate of 78%. The tissue was evaluated using IHC staining
for Ki-67 and chromogranin A (CGA). On multivariate
analysis, Gleason score > 4 + 3, CGA positive, lymph node
positive, PSA > 20ng/mL, and Ki-67 were prognostic, while
pathologic stage T3 and margin positivity were not. For the
300 Ki-67 ≥ 5% patients, 5-year biochemical recurrence-
free survival (from graph) was 70%, while for the 228
with <5% staining, it was 88%. In another large study,
Miyake et al. [9] studied 193 prostatectomy patients that
did not receive adjuvant treatment. With a median followup
of 63 months, 21% failed for a 5-year disease-free survival
rate of 79%. They evaluated twelve markers with IHC.
On univariate analysis, they found the following factors to
be prognostic: PSA, Gleason score, lymph node positivity,
tumorvolume, seminal vesicleinvolvement,margin positive,
and on immunohistochemical staining: Ki-67, p53, AR,
MMP-2, MMP-9, and HSP27. On multivariate analysis, only
Ki-67, seminal vesicle involvement, and margin positivity
remained signiﬁcant. In consideration of those three positive
factors, if the patient was positive for 2 or 3 of them, the
recurrence rate was 79%, if positive for one, 20%, and ifProstate Cancer 3
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.4 Prostate Cancer
negative for all 3, 4%. Ki-67 was also prognostic in a smaller
study of 91 prostatectomy only patients [10]. With a median
followup of 46.5 months, 29 (32%) progressed (PSA ≥
0.2ng/mL). For the 60% of patients with <5% PSA staining,
5-year disease-free survival was 84%, compared to 42% for
those with ≥5% staining (from graph). On multivariate
analysis, Ki-67 and Gleason score were prognostic. The
ﬁnal positive study was a multifactorial study [11]o f
336 RRP patients, of which 249 had tissue. Lymph node
positive patients were included. Failure was deﬁned as PSA
> 0.5ng/mL. Five-year DFS was 63%, and 10-year was
41% with a median followup of 66 months. They utilized
immunohistochemical staining for Ki-67, enhancer of zeste
homolog2(EZH2),(discussedbelow)andminichromosome
maintenance protein 7 (MMC7) (discussed below). They
also used ﬂuorescence in situ hybridization (FISH) for
EIF3S3, a chromosome abnormality they had explored
previously. On multivariate analysis considering EZH2, Ki-
67, MCM7, Gleason score, pathologic stage, and PSA, the
factorsofpathologicstage,Ki-67andMCM7weresigniﬁcant
predictive factors. From the graphs, for staining 0-1%, 10-
year disease-free survival was 65%, for 2–15% was 38%,
and for >15% was 27%. Demonstrative as to how other
factorscanhaveaneﬀectofprognosticability,inpatientsthat
were lymph node negative with an undetectable postsurgery
PSA, Ki-67 dropped out and EZH2, MCM7, and PSA were
prognostic. In Gleason, less than 7 patients, Ki-67 was the
only signiﬁcant factor; the 15 patients with Ki-67 staining
of >1% had a 5- and 10-year disease-free survival of 70%
and 45%, respectively (from the graph), compared to 100%
for Ki-67 of 0-1%. No details of interaction with pathologic
variables were given.
Even though those studies showed on multivariate
analysis Ki-67 was able to predict failure, other than the
correlation shown in the Miyake et al. study [9], none of the
studies evaluated as to how Ki-67 improved the predictive
ability of the standard prognostic factors. Therefore, its
utility remains uncertain, which is further compounded by
the studies that show that Ki-67 is not predictive for failure.
In that regard, in a study of 162 patients undergoing RRP
(median followup 4.5 years, PSA failure > 0.2ng/mL at least
twice),Ki-67staining was measured <2in62%ofthetumors
and 2–4 in 38% [4]. On multivariate analysis including
pathology stage, race, Gleason score, age, p53, bcl2, and Ki-
67 (MIB-1) levels, p53 and bcl-2 were prognostic, but not
Ki-67. The ﬁndings were conﬁrmed in another study of the
same patients[12].Fromthecohortof335patients,thistime
180had available tissue. With a mean followup 4.4years, and
failure deﬁned as PSA > 0.2ng/mL twice, the overall 5-yr
biochemicalfailure-free survival(BFFS)was60%.Ninetyper
cent had measurable Ki-67 (MIB-1) staining. In 18 patients
with negative or rare Ki-67 staining, 3 (5%) progressed
for an 83% 5-year biochemical-free survival (BFFS); of 90
that stained 1+, 23 (37%) progressed for a 69% 5-year
BFFS; and in 72 that were 2–4+, 36 (58%) progressed with
a 5-yr BFFS of 44%. On multivariate analysis, stage and
Gleason score were signiﬁcant prognostic factors and Ki-67
was only marginal. In a subgroup analysis, Ki-67 appeared
to diﬀerentiate failure in Gleason 2–6 patients, but not in
higher grade. A third paper including at least some of the
same patients (132) [13] showed Ki-67 positive patients had
a higher recurrence rate but again the ﬁndings were not
signiﬁcant on multivariate analysis. In a diﬀerent approach
[14], 41 prostatectomy patients who failed within two years
(PSA > 0.2ng/mL) were matched for pathologic stage, PSA,
and Gleason score with 41 patients who did not have a rising
PSA by three years. They found no diﬀerence in Ki-67, p53,
andbcl-2betweenthetwogroups.Finally,inanevaluationof
112 prostatectomy patients [15] ,f o rp a t i e n t sw i t hl o wM I B -
1 staining, the 5- and 10-year clinical disease-free survival
was 75% for both, and for high staining patients was 52 and
42%, respectively. In spite of this diﬀerence, MIB-1 was not
predictive of recurrence or death on multivariate analysis.
3.2. Apoptosis-Related Markers (p53, bcl-2, and MDM2).
Cellular stress triggers (upregulates) p53, which accumulates
in cells and leads to either cell cycle pause and repair or
apoptosis. Loss of p53 function potentially can allow a
cell that would normally undergo apoptosis to survive an
otherwise lethal event. Bcl-2 is antiapoptotic and elevated
levels can also conceptually allow cells to survive an other-
wise lethal event. Mouse double minute-2 (MDM2) has an
antiapoptotic eﬀect by binding to p53 and inactivating it.
Wild-type or normal p53 is cleared rapidly from cells, so
measurable p53 is usually dysfunctional. Therefore, counter-
intuitively, an elevated p53 actually represents decreased p53
function.
As with Ki-67, there are several positive and negative
studies (Table 2). In 71 patients operated on before 1984
[16] with a median followup of 10.6 years, 15-year cause-
speciﬁc survival for p53 positive patients was 38% and for
p53 negative patients was 87%. They also found that the
15-year cause-speciﬁc survival for retinoblastoma protein
(Rb) positive patients was 66% and Rb negative was 92%.
On multivariate analysis, the combination of p53 and Rb
was the strongest predictor of failure. There was no analysis
with the common prognostic factors (stage, PSA, or Gleason
score). A later study in 76 RRP patients with a median
followup of 50 months found that 27% of the patients with
<40% positive p53 staining recurred versus 6/10 (60%) with
more than 40% staining [17].On univariate analysis, nuclear
grade, pathologic stage, and p53 were signiﬁcant, but on
multivariate analysis, only p53 was signiﬁcant. In another
prostatectomy study, 263 patients had a mean followup of 55
months and39% failed [18].Seventy-eightreceived adjuvant
treatment. They found clustering of p53 positive cells (>12
c e l l s )t ob em o r ep r e d i c t i v et h a np e r c e n t a g eo fp o s i t i v ec e l l s .
On multivariate analysis, both clustering and percentage p53
positive, along with PSA, path stage, Gleason score, and
lymph node positivity were predictive for failure.
Several studies have considered p53 in conjunction with
otherfactorssuchasbcl-2,andKi-67.Inonestudyconsisting
of 162 patients undergoing RRP (median followup 4.5 years,
PSA failure > 0.2ng/mL at least twice) p53 was measured
negative in 31% of the tumors and positive (1–4+) in
69%. Bcl-2 was measured negative in 73% of the tumors
and positive (1–4+) in 27% [4]. On multivariate analysisProstate Cancer 5
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including pathology stage, race, Gleason score, age, p53, bcl-
2, and Ki-67 (MIB-1) levels, p53 and bcl-2 were prognostic.
There was no correlation as to what the markers added to
the common prognostic markers. In another study from
the same patient cohort, 175 patients underwent radical
prostatectomy [19]. With a mean followup of 4.6 years, p53
staining was positive in 65% and the 5-year failure rate
was 51%, compared to 22% for the patients that stained
negative. Bcl-2 staining was positive in 27% and the 5-year
failure rate was 67%, compared to 31% for the patients that
stained negative. For patients that were both p53 and bcl-
2 positive, the ﬁve-year failure rate was 75% compared to
20% for those that were negative for both. On multivariate
analysis, stage, race, bcl-2, and p53 were all prognostic.
Again, there was no indication of whether they enhanced
the standard markers. Interestingly, in yet another analysis of
some of the same patient cohort (132 patients) with median
followup of 3.9 years, p53 positive patients had a higher
recurrence rate but it was not signiﬁcant on multivariate
analysis [12]. Another study of p53 and bcl-2 looked at
76 prostatectomy patients with a mean followup of 38
months, 23 (30%) of whom failed [20]. Fifty-seven percent
were p53 positive on prostatectomy tissue and 41% failed
comparedto21%with normalp53.Twenty percentwerebcl-
2 aberrant on prostatectomy tissue and 53% failed compared
to 24% of those with normal bcl-2. In an additional study of
119 radical prostatectomy patients receiving no neoadjuvant
treatment and with a median followup of 3.3 years, 16
(13%) failed [21]. On multivariate analysis, bcl-2, p53, Ki-
67, PSA, Gleason score, Capsular penetration, age, and
margin positivity were not predictive, but SV involvement
and caveolin-1 (see below) were.
In an older cohort of patients (22% of the failures
predated PSA), 30 received adjuvant treatment (mostly
radiation) [22]. With a mean followup of 5.2 years, bcl-
2 positivity was predictive of recurrence, but only stage
pT3 and Ki-67 were predictive of failure (not p53). From
the graph, for elevated bcl-2, 10-year disease-free survival
was 18% and for nonelevated bcl-2 was 52%. Only 8%
overexpressedp53.Likep53,itisalsonotuncommonforbcl-
2 staining to be too low (<5%) to be meaningful [10].
Miyake et al. evaluated 193 prostatectomy patients with
twelve markers on IHC, including p53 [9]. While it was
predictive on univariate analysis, it was not on multivariate.
Bcl-2 was not predictive for either. In a study of 70
pathological T2 patients[23] with a median followup of 36.5
months, 30% suﬀered biochemical relapse (PSA> 0.2ng/mL
times two), sixteen patients were p53 positive, and 44%
suﬀered PSA relapse which was not signiﬁcantly diﬀerent
than the p53 negative patients (26% relapse). Only 3 (4%)
patientswere bcl-2positive, but2 (67%)relapsed, which was
signiﬁcantly higher than the bcl-2 negative patients (28%
failure). Finally, in a study [24] of 86 patients (median
followup 65 months) with an undetectable PSA after radical
prostatectomy (38% received neoadjuvant treatment), 20%
overexpressed p53 and had a higher risk of relapse. The 33%
that overexpressed MDM2 also had a higher risk of relapse.
No details were given, but on multivariate analysis, both p53
and p21 were predictive. Stage and MDM2 were not. Inter-
estingly, there was no association with p53 overexpression
and p21 or MDM2. As with all the studies discussed, there
w a sn or e a la n a l y s i sf o rc o r r e l a t i o nw i t hs t a n d a r dp r e d i c t i v e
factors, so the real predictive powerof these markers remains
elusive.
3.3. E-Cadherin and Other Adhesion Molecules. Calcium-
dependent adhesion molecules (cadherins) are transmem-
brane proteins that play a role in cell adhesion. E-cadherin
is a subtype found in epithelial tissue with extracellular,
transmembrane, and intracellular domains. The intracellular
domain binds to beta catenin. In cancer, E-cadherin down-
regulation theoretically reduces cell adhesion resulting in
increased cell motility and dissemination.
In a study of 70 pathological T2 patients [23]w i t ha
median followup of 36.5 months, 30% suﬀered biochemical
relapse (PSA > 0.2ng/mL times two). Thirty-nine patients
(56%) had aberrant E-cadherin staining, with a 44% PSA
relapse rate, which was signiﬁcantly worse than those
with normal E-cadherin staining (13% recurrence). In 104
prostatectomy patients [25] (7 lymph node positive), low E-
cadherin,Gleasonscore,andpathologicstagewerepredictive
of biochemical failure (PSA > 0.5ng/mL) on multivariate
analysis. For clinical failure, pathological stage dropped out
and elevated N-cadherin was signiﬁcant. For patients with
low E-cadherin, the 10-year biochemical failure-free survival
was 14%, versus 33% for those with elevated levels. For N-
cadherin, low levels resulted in 33% biochemical failure-
free survival and high levels 14%. They found that the E-
cadherin to N-cadherin ratio was more powerful than either
alone, but did not provide speciﬁcs nor any details on the
modiﬁcation of the predictive power of standard factors.
In a study of 67 radical prostatectomy patients [26]w i t ha
median followup of 54 months, 27 (40%) recurred clinically,
7 locally, and 20 systemically. When evaluated with IHC for
E-cadherin, a cut point of 40% staining was chosen. For
the 13 that stained less than 40%, 2 (15%) died of cancer
and for the 54 that stained >40%, 14 (26%) died of cancer,
but the diﬀerence was nonsigniﬁcant. E-cadherin was not
predictive on univariate or multivariate analysis for either
recurrence or survival. In 128 radical prostatectomy patients
[27] without adjuvant treatment, tissue microarrays were
made and stained withIHCstaining. Normalwas considered
>70% staining. For nonmetastatic prostate cancer, 18%
had aberrant staining. With a median followup of 23
months, 38% of the failures and 20% of the nonfailures
had aberrant staining, a nonsigniﬁcant diﬀerence. Similarly,
in a microarray study (discussed below), Rhodes et al. [28]
found that a decreased E-cadherin to EZH2 ratio resulted
in an increased rate of biochemical failure after radical
prostatectomy.
Brewster et al. [20] studied 76 prostatectomy patients;
49% were E-cadherin aberrant on prostatectomy tissue and
37% failed compared to 22% with normal E-cadherin. On
multivariate analysis, it was not predictive when considered
with p53, bcl-2, Gleason score, and margins. They also
evaluated another apparent adhesion molecule in the form
of the cell surface glycoprotein CD44. Sixty-four percentProstate Cancer 7
were CD44 minimal or absent on prostatectomy tissue. Of
those with normal staining, 8% failed compared to 43%
with aberrant staining. On multivariate analysis, it was not
predictive when considered with p53, bcl-2, Gleason score,
and margins. Two other studies evaluated CD44. In 97
radical prostatectomy patients [29] with median followup
of 84 months, utilizing PSA of >1.0 as failure, most (86%)
patients were positive for CD44, so risk was determined
by graded intensity of the staining. Decreased expression
increased the risk of failure. On univariate analysis, loss of
CD44 and cd4v6 were predictive of clinical failure, but only
CD44 was predictive for biochemical failure. In the other
study, 99 patients had mean followup of 40 months and 26%
suﬀered a biochemical recurrence [30]. CD44 was evaluated
via an intensity and percent staining score, and 47% were
downregulated. The 3-year recurrence-free survival was 77%
for the nondown-regulated patients versus 48% for those
withCD44downregulation.Itwas notasigniﬁcant predictor
on multivariate analysis, when considered with p34.
In none of these studies was there an assessment of how
it modiﬁed the predictive ability of the standard prognostic
factors.
3.4. EZH2. The Enhancer of Zeste 2 (EZH2) gene codes for
polycomb group proteins that eﬀect chromatin and silence
genes. When overexpressed, it appears to be associated with
tumorigenesis. In a study involving multiple cancers [31],
104 radical prostatectomy patients with a median followup
of 104 months were evaluated with staining for EZH2. For
lowEZH2staining, the5- and 10-yearcause-speciﬁc survival
was 99% and 93%, respectively. For the high staining group,
it was 89% and 53%, respectively. On univariate analysis,
upper quartile EZH2 staining was predictive for clinical
recurrence and on multivariate analysis was predictive for
distant metastasis and death. In another study of 64 patients
[32], tissue was stained for EZH2and if the intensity was ≥3,
10/32 (31%) failed versus 3/32 (9%) if the staining was <3.
It was a signiﬁcant factor on multivariate analysis along with
margin status, tumorsize, Gleason score,and PSA.Finally, in
as t u d y( s e eK i - 6 7a b o v e )[ 11] of 249 prostatectomy patients,
ﬁve- and 10-year disease-free survival was 63% and 41%,
respectively. On multivariate analysis, pathologic stage, Ki-
67 and MCM7 were signiﬁcant predictive factors (EZH2
was not). In patients that were lymph node negative with
an undetectable postsurgery EZH2, MCM7 and PSA were
prognostic. In Gleason less than 7 patients, Ki-67 was the
only signiﬁcant factor. There was no evaluation of whether
this added to the predictive ability of standard factors.
3.5. Cyclin-Dependent Kinases (and Their Eﬀectors). Cyclin
dependent kinases (CDKs) are protein kinases involved in
the regulation of the cell’s progression though the cell cycle.
As most cancers have dysfunctional cell cycle control, the
kinases are implicated as part of the aberrancy. Cyclin D1
is speciﬁc for transition through G1/S. It has its eﬀect by
binding with cyclin dependent kinases 4 and 6 forming a
complex that phosphorylates and inactivates the retinoblas-
toma protein (Rb). Overexpression of cyclin D1 has been
associated withthemalignantphenotypeanditsprogression.
There are several known inhibitors of cyclin dependent
kinases. For example, p16INK4a (cyclin-dependent kinase
inhibitor 2A) inactivates Cdk4 and CdK6 and thereby acts
as a tumor suppressor (by blocking the phosphorylation of
the Rb gene, which prevents transit through G1). Loss of
p16 enables abnormal progression through the cell cycle,
increasing the malignant potential. P21-waf1 encodes a
cyclin dependent kinase inhibitor (p21 or cyclin dependent
kinase inhibitor 1A), inhibiting CDKs 2 and 4, which leads
to arrest at G1. It is induced by p53 (thus elevated p53
can lead to arrest at G1 through this route). P27Kip1
(cyclin dependent kinase inhibitor 1B) is also involved in
G1 arrest by inhibiting cyclin dependent Cdk2 complexes
E and A and D-Cdk4. Therefore, a decrease in p27 should
resultinincreasedproliferation.Lastly,p34cdc2(celldivision
control protein 2) is a component that forms a kinase
by binding with cyclin B1 (forming maturation-promoting
factor (MPF)) that regulates G2/M transition and promotes
mitosis).
In a study [24] of 86 patients with an undetectable PSA
after radical prostatectomy (38% received neoadjuvant treat-
ment), 33% overexpressed p21Cip, and this was associated
with a higher risk of relapse. No details were given, but on
multivariate analysis, both p53 and p21 were predictive of
relapse whereas stage and MDM2 were not.
In one study, where the primary goal was to assess the
association between pathological features and biomarker
expression [33], p27Kip expression was evaluated in 113
prostatectomy specimens (median followup 4.6 years, 21%
neoadjuvant androgen ablation), and correlated with out-
come. Low p27 nuclear staining was a poor prognostic sign.
On multivariate analysis, p27, seminal vesicle status and
margin status were all predictive for recurrence, but no
details were given. In a second study of 96 stage C lymph
node negative patients undergoing radical prostatectomy
with a median followup of 9.5 years [34], p27 Kip1 staining
correlated with Gleason score (higher grades had decreased
levels). The 9-year recurrence-free survival for levels ≤10%
was 17%, for levels 11–50% was 47%, and for >50% was
67%. There was no correlation with the standard factors.
In a third p27 study [35] of 86 patients (after excluding
thosethatreceivedadjuvanttreatment),multivariate analysis
demonstrated only pathologic stage and p27 to be predictive
at a median followup of 40 months. High Gleason score
was associated with low p27 staining. Thirty percent was the
breakpoint between high and low staining. Fifty percent of
patients with low staining failed (PSA > 0.4) and 78% with
high staining failed. In another study with 95 patients [36],
loss of p27 (<10%) on multivariate analysis was signiﬁcant
for recurrence, but not for survival. With a median followup
of 49 months, 33% of the p27 negative patients failed versus
23% for the p27 positive patients (median followup 59
months). Another study was of 161 prostatectomy patients
[37], which were divided into organ conﬁned (n = 76,
median followup 42 months) and nonorgan conﬁned (n =
85, median followup 38 months) patients. p27 staining
was performed on the biopsy, but not the ﬁnal pathology
specimen, and patients were not evaluated for the speciﬁc8 Prostate Cancer
impact of positive margins, seminal vesicle involvement, or
lymph node involvement. For the organ-conﬁned patients,
the 5-year recurrence rate was 26%, but 9% for those with
high p27 staining and 37% with low (<45%) staining. In this
subgroup, p27 was predictive for failure. In the nonorgan
conﬁned patients, the recurrence rate was 44%, but p27 was
n o tp r e d i c t i v eo ff a i l u r ei nt h e s em o r ea d v a n c e dp a t i e n t sa n d
the actual eﬀect on failure was not stated. In an evaluation
[15] of 112 prostatectomy patients, 92 had adequate p27
staining. Thirty-ﬁve (38%) stained less than 50% and were
classiﬁed as low staining. Based on clinical parameters, their
5- and 10-year disease-free survival were 37% and 26%,
respectively. For the high staining patients, it was 79% and
77%, respectively. p27 predicted for clinical recurrence and
cause-speciﬁc survival.
Finally, in a study of 104 radical prostatectomy patients
with a median followup of 56 months [38], p27 was
determined by the per cent of nuclei staining, with the
median of 64% used as the breakpoint between high and
low. On multivariate analysis, pathologic stage and PSA were
signiﬁcant predictors of recurrence, but not p27.
p16 has been evaluated in several studies. In 206 radical
prostatectomy patients (18% with neoadjuvant androgen
ablation) with a median followup of 72 months, one group
[39] found positive p16INK4a staining to be associated
with recurrence. On multivariate analysis, p16, PSA, Glea-
son score, and margin status were all predictive, but no
actual outcome data was given. In another study [40], 88
prostatectomy patients (39% neoadjuvant treatment) with
a median followup of 65 months stained for P16. Unlike
Henshall et al. [39] (which called low <1%),their breakpoint
was 5% positive nuclear staining. For the 38 patients that
overexpressed, 21 (55%) failed versus 26% of the 50 under
expressing patients. p16 was associated with PSA levels and
was not an independent prognostic factor on multivariate
analysis. They also did not report speciﬁcs on outcome.
In a third study of 104 radical prostatectomy patients with
a median followup of 56 months [41]t h em u l t i v a r i a t e
analysis for survival was positive for p16, age, grade, capsular
penetration, and seminal vesicle involvement. They scored
p16 by a ﬂuorescence index. The low group had a 5-year
survival of 78% versus 43% for the intermediate group (P =
.005) and 42% for the high index group. There was no
outcome data accounting for the standard factors. Ploidy or
Sp h a s ew a sn o tp r e d i c t i v e .
In analysis of cyclin D1 and p34cdc2, 140 patients [42]
with a median followup of 42 months were evaluated.
Failure was deﬁned as a PSA > 0.4. In patients that were
p34cdc2 negative, 10% failed versus 26% that were positive.
For Gleason 7 or greater, the failure rate was 26% for
p34cdc2 negative and 38% for positive. On multivariate
analysis, only p34cdc2 and Gleason score were predictive
and cyclin D1 and ploidy were not. p34 was also evaluated
in a study of 99 patients. With a mean followup of 40
months, 26% suﬀered a biochemical recurrence [30]. p34
was evaluated via an intensity and percent staining score
and 61% were determined to have overexpressed p34. The
4-year recurrence-free survival (from the curves) was 98%
f o rt h en o n o v e re x p r e s s e dp a t i e n t sv e r s u s4 7 %f o rt h o s eo v e r
expressing p34. It was a signiﬁcant predictor on multivariate
analysis, but there was no evaluation of whether it enhanced
the predictive ability of standard factors.
3.6. Cathepsin-D. Cathepsins are proteases (i.e., involved
in protein degradation) usually housed in lysosomes that
proteolyse proteins that regulate cell growth. In a study
[43], 105 radical prostatectomy patients were evaluated for
cathepsin D. It was not prognostic on either univariate or
multivariate analysis, but probably because the expression
rate was extremely high at 98%.
3.7. Chondroitin Sulfate. Chondroitin sulfate is a structural
glycosaminoglycan of the extracellular matrix that helps
regulate cell activity. Ricciardelli et al. [44] studied 157
prostatectomy patients after exclusion of adjuvant and
neoadjuvant treatment; failure was deﬁned as a PSA >
0.2 and median followup was 47 months. They used an
antibody to chondroitin sulfate and read the slides via an
image capture technique with automated analysis. There
was a twofold diﬀerence between this study and previous
studies for the absolute value of the mean due to calibration
diﬀerences, which demonstrates the lack of uniformity in
these studies. The median was chosen as the cut point,
although the most robust point was slightly above that.
On multivariate analysis, chondroitin sulfate, Gleason score,
preoperative PSA, and pathological stage were all predictive.
For patients with low staining, 23% failed for a 5-year PSA
failure rate of 33% versus 51% with high staining failing
f o ra5 - y e a rf a i l u r er a t eo f5 1 % .T h e r ew a ss o m ec o r r e l a t i v e
analysis between chondroitin staining and other predictive
factors. Forpatientswith a preoperativePSAlessthan10,9%
with low chondroitin sulfate staining failed versus 48% with
high levels. In a more speciﬁc analysis, the ﬁve-year failure
rate forGleason 5–7 patientswith low chondroitin levelsand
low PSA was 11% compared to 44% for low chondroitin
staining patients with a high PSA. Further, Gleason 5–7
patients with high chondroitin sulfate staining and low PSA
had a ﬁve-year failure rate of 56% versus 72% for high
staining and high PSA. There was no evaluation done with
the integration of pathology ﬁndings.
3.8. Hepsin and PIM1. Hepsin is a transmembrane serine
protease whose exact function is unknown, but when
upregulatedappearstoexpressamalignantphenotype.PIM1
encodes a protein kinase that promotes G1/S transition by
upregulation of CDK2, facilitating cell proliferation and
survival. One study [45] utilized human specimens and
cell lines for comparison of malignant and benign tissue.
Out of several hundred candidate genes, hepsin and PIM1
expression proteinswere selected forfurther analysis. Hepsin
was increased in malignant prostate tissue versus benign,
but staining was greatest in PIN. In radical prostatec-
tomy patients, low or absent hepsin increased failure. On
multivariate analysis, both hepsin and Gleason score were
predictive of failure. They also tested for PIM1. It was
upregulated in prostate cancer and decreased levels were
associated with increased PSA level in 135 patients withProstate Cancer 9
localized prostate cancer. It was signiﬁcant on multivariate
along with Gleason score 4-5 and PSA. They concluded
that lower PIM1 levels were strongly associated with an
increased risk of relapse. There was no outcome correlation
with standard factors with either marker.
3.9.Cox-2. Inastudyof91prostatectomy patients[10],with
a median followup of 46.5 months, 29 (32%) progressed
(PSA > 0.2ng/mL). A score was developed for percent and
intensity of staining for Cox-2. For no staining, the failure
rate was 26% versus 60% for 1–4, but then dropped back to
15% for 5–12. While it was a predictive marker on univariate
analysis, it was not on multivariate.
3.10. Laminin Receptor (Ribosomal Protein SA). Laminins
are glycoproteins located in the basement membrane (basal
lamina) that aﬀect cell adhesion and migration as well
as diﬀerentiation and survival. Laminin receptor (LR) is
detected via the MLuC5 antibody. In an initial evaluation
[46] in 140 patients, it appears that laminin receptor
positivity might be associated with recurrence. Overall, the
3-year biochemical failure-free survival was 68%, but for
LR positive patients the failure was 45% and for negative
patients it was 7%. There was no correlation with PSA
and Gleason score. The followup was only 20 months, and
a later paper [47] showed that LR measurement of the
biopsy tissue was not signiﬁcantly predictive for biochemical
progression, probably due to a lack of concordance between
the measurements in biopsy tissue versus the larger tumor
specimen.
3.11. Chromogranin A (CGA). In a study of 528 prosta-
tectomy patients [8] excluding neoadjuvant and adjuvant
androgen ablation and radiation therapy, with a median
followup of 46 months, 101 (19%) failed for a 5-year
disease-free (PSA < 0.2ng/mL) rate of 78%. The tissue was
evaluated using IHC staining for Ki-67 and chromogranin
A (CGA). On multivariate analysis, Gleason score > 4+
3, CGA positive, lymph node positive, PSA >20ng/mL,
and Ki-67 were prognostic, while pathologic stage T3 and
margin positivity were not. For the 32 CGA positive patients,
the 5-year biochemical recurrence-free survival was 48%
and for the 496 CGA negative it was 80%. Because of the
small number of CGA positive patients, the only speciﬁc
information was given on whether there was modiﬁcation of
prognosisofthestandardfactorswasforGleason<7patients,
where for the 304 CGA negative patients, 8% failed and for
the 12 CGA positive, 25%.
3.12. Minichromosomal Maintenance Protein 7 (MCM7).
Minichromosome maintenance protein 7 (MCM7) appears
to be a facilitator of DNA replication, so upregulation would
be expected to increase proliferation. It has been found on
microarray analyses that MCM7 is frequently ampliﬁed in
prostate cancer. In an evaluation of prostatectomy patients
[48], 52/68 (77%) with MCM7 ampliﬁcation relapsed versus
7/57(12%)withoutampliﬁcation.Inastudydiscussedabove
(see Ki-67) [11], pathologic stage, Ki-67, and MCM7 were
signiﬁcant predictive factors. In evaluation of patients that
were lymph node negative with an undetectable postsurgery,
EZH2, MCM7, and PSA were prognostic. In both studies,
there was no clinical correlation, so these interesting ﬁndings
are of uncertain signiﬁcance.
3.13. Histones. Histones are intranuclear proteins in chro-
matin around which DNA is “wound”, the modiﬁcation of
which inﬂuences their interaction with the DNA and aﬀects
some processes such as mitosis and gene regulation. In 183
radical prostatectomy patients, those that received androgen
ablationwere excluded.The medianfollowupwas60months
and failure was deﬁned as PSA > 0.2ng/mL [49]. In order
to evaluate sites on histones H3 and H4 with acetylation
and dimethylation staining, 5 diﬀerent sites were identiﬁed
by using a clustering algorithm. While not independently
predictive, when combined with Gleason score, the ﬁndings
yielded prognostic information. From the graph, Gleason <
7 patients that were histone “favorable” had an 84% disease-
free survival, while those unfavorable had a 58% disease-
free survival. For Gleason 7–10, the favorable group had a
disease-free survival of 46% versus 20% for the unfavorable.
3.14. TMPRSS2:ERG Fusion. TMPRSS2 (transmembrane
protease, serine 2) is an androgen-regulated gene found on
chromosome 21 that encodes a transmembrane protease. In
prostate cancer, it can be fused with genes for the ETS tran-
scriptionfactors,suchasERG(resultinginTMPRSS2:ERG).
This indirectly places ERG under androgen transcriptional
control. There are multiple variants of this fusion. This can
be detected through either RT-PCR or ﬂuorescence in situ
hybridization (FISH). In 165 prostatectomy patients with
a v a i l a b l ef r o z e nt i s s u e[ 50] with a median followup of 20
months, tissue was evaluated for TMPRSS2:ERG fusion
gene and 49% was positive. For the fusion gene positive
patients, 46% failed compared to 7% in fusion negative
patients. On multivariate analysis, the fusion gene was the
most predictive factor, followed by grade. Evaluation was
made for diﬀerent Gleason and pathologic ﬁndings. For
Gleason 5-6 patients, 33% of the gene positive patients
failed, versus 5% for the gene negative. For Gleason 7
and Gleason 8–10, it was 48% versus 7% and 75% versus
14%, respectively. For organ-conﬁned patients, gene positive
patients had a recurrence rate of 34% versus 10% for gene
negative. For extraprostatic extension and seminal vesicle
positive patients, it was 53% versus 3% and 67% versus
34%, respectively. For both Gleason score and pathological
ﬁndings, all the diﬀerences were statistically signiﬁcant,
except for the seminal vesicle involved patients. Another
study, started with 248 radical prostatectomy patients [51],
but only 150 were ultimately evaluable by FISH. Of those, 50
(33%) were found to have TMPRSS2:ERG rearrangement.
With a median followup of 66 months and failure deﬁned as
two rises of PSA > 0.5ng/mL, on multivariate analysis, Ki-
67, pathologic stage, and TMPRSS2:ERG fusion were signif-
icant, not Gleason score or PSA [52]. Yoshimoto et al. evalu-
ated specimens from 125 radical prostatectomy patients, 122
of which had clinical followup and with a median followup,10 Prostate Cancer
49% had failed (PSA > 0.2ng/mL). Neoadjuvant androgen
ablation was allowed, and 2 patients were lymph node
positive. FISH was used to evaluate for TMPRSS2:ERG, and
48% were found to have rearrangements resulting in a 5-
year biochemical failure-free survival (BFFS) of 46%. For
those that were negative, 5-yr BFFS was 62% (P = .0523).
Expanding on their previous work, they also evaluated
for PTEN deletion by FISH. Only 82 of the 125 patients
could be evaluated. There was no diﬀerence in 5-yr BFFS
between those that were deletion negative and positive, but
if they divided the deleted patients into hemizygous and
homozygous deletions, they found that all the homozygous
patients had failed by 5 years. If patients had both the PTEN
deletion and the TMPRSS2:ERG fusion, 5-yr BFFS was 30%
versus 59% if they had neither (P = .001). They did not
test to see whether these markers augmented the predictive
ability of the three standard factors (Stage, Gleason score, or
PSA), although on multivariate analysis only Gleason score,
the TMPRSS2:ERG/PTEN combination and homozygous
PTEN deletion were prognostically signiﬁcant. A study [53]
using microarray to compare genes between benign and
malignant cells found that ERG was the most commonly
over expressed. Then utilizing QRT-PCR, they analyzed 114
prostate cancer patients and found ERG1 over expressed in
62%. Ninety-ﬁve patients had detectable levels and for a
>100 over expression, the 5-year biochemical failure free-
survival (from the graph) was 88%, for 2–100 fold 80%
and for <2 fold 36%. On multivariate analysis, ERG1 (>100
versus <2) and Gleason (8–10)were signiﬁcant, butnot race,
PSA, pathologic stage, margin positive, or seminal vesicle
positivity.
Not all studies found TMPRSS2:ERG to be prognostic.
In one study [54], two subgroups were taken from larger
prospective studies and ultimate outcome collected from
SEER data. This yielded no failure data and only crude
followup of cancer-speciﬁc survival. Of the subgroups,
only 57% could be scored for the fusion. They reported
no association between the occurrence of TMPRSS2:ERG
(positive in 36% of the patients) and cancer speciﬁc survival.
Researchers in a study [55] of 521 radical prostatectomy
patients with 95 month median followup utilized FISH and
found 42% had TMPRSS2:ERG abnormalities. It was not
associated with recurrence, metastasis or death. Finally, in a
study of 54 patients [56], 35 (65%) had gene rearrangement,
which was present in 60%ofthenonfailing patients and 65%
ofthe failing patients. Inthe evaluationof 28benign prostate
tissues, there were no rearrangements.
3.15. PTEN. The phosphatase and tensin homologue
(PTEN) gene modulates the phosphotidylinositol 3-kinase
(PI3K) pathway, a regulator of the Akt pathway. Lack of
PTEN allows for upregulation of Akt and other cell cycle
factors, increasing cell survival. As noted above [52]i n
the TMPRSS2:ERG discussion, on multivariate analysis,
homozygous PTEN deletion and the TMPRSS2:ERG fusion
wereprognosticallysigniﬁcant.Inanearlierstudyspeciﬁcally
evaluatingPTEN,thesame authors[57]utilizedﬂuor escence
in situ hybridization (FISH) to PTEN in 107 prostatectomy
patients. Tissue was scored as showing no deletions (56%),
hemizygous deletions (39%), or homozygous deletions
(5%). On Cox proportion hazard analysis, for univariate
analysis, perineural invasion, seminal vesicle positive (SV+),
extraprostatic extension (EPE), Gleason score, PSA, lymph
node positivity, and PTEN deletion were all predictive. On
multivariate analysis, only EPE, SV+, and PTEN were pre-
dictive. For PTEN, from the graph, 5-year PSA (>0.2ng/mL)
failure-free survival was 0 for the 5 homozygous patients,
48% for the 42 hemizygous patients, and 60% for the 60
patients without deletion. There was no discussion as to how
PTEN modiﬁed the predictive ability of standard factors.
In a separate study of 104 radical prostatectomy patients
with a median followup of 56 months [38], PTEN was
scored as an index based on percent staining and intensity.
On multivariate analysis, pathologic stage and PSA were
signiﬁcant predictors of recurrence, but not PTEN.
3.16. Epidermal Growth Factor Receptors (EGFR). Epidermal
growth factors are extracellular ligands controlled by the
cell surface epidermal growth factor receptors, which are
tyrosine kinase receptors. When activated, they initiate a
cascade of signal transduction (i.e., though the Aktpathway)
that results in cell proliferation. If the receptor is mutated
in the “on” position (i.e., over expression), the result could
be uncontrolled proliferation. Her-2/neu (c-erb B2) encodes
a tyrosine kinase growth factor receptor similar to the
epidermal growth factor receptors and has been linked with
advanced disease. In one study, [43] 105 radical prostatec-
tomy patients were evaluated for epidermal growth factor
receptor (EGFR). The expression rate was 48%, but it was
not prognostic on either univariate or multivariate analysis.
In 113 prostatectomy patients with a mean followup of 42
months [58], utilizing IHC, membranous and cytoplasmic
staining was given a composite score so that ≥3w a s
considered positive. With that parameter, 29% of the tissue
over expressed and there was no correlation with failure on
univariate analysis. Utilizing FISH, it was found that 41%
were ampliﬁed for Her2, but there was poor correlation
with IHC staining (P = .25). While FISH analysis was
signiﬁcant for failure on univariate analysis, it was not a
signiﬁcant predictor of failure on multivariate analysis. In 99
patients with a mean followup of 40 months, 26% suﬀered
a biochemical recurrence [30] .H e r2 - n e uw a se v a l u a t e d
via FISH and 42% were found to be ampliﬁed. The 5-
year recurrence-free survival was 75% for the nonampliﬁed
patients versus 47% for those with Her 2-neu ampliﬁcation.
It was not a signiﬁcant predictor on multivariate analysis,
when considered with p34.
3.17. VEGF. In a study of 193 prostatectomy patients [9],
twelve markers were evaluated on IHC, including VEGF, but
it was not predictive on univariate analysis.
3.18. Caveolins. Caveolins are cell membrane proteins
involved in endocytosis resulting in invagination of the
plasma membrane (caveolae). They appear to be involved inProstate Cancer 11
signal transduction with a role in homeostasis and tumori-
genesis. Caveolins have been found to be both increased and
decreased in cancer so their role is variable and uncertain.
In radical prostatectomy patients selected for failing or not
failing, 162 lymph node negative patients were identiﬁed.
With immunohistochemical staining for caveolin 1, 22%
werepositiveand ﬁve-year progression-free survival was 43%
versus 68% for those that were negative. On multivariate
analysis, caveolin 1, Gleason score, extracapsular extension,
seminal vesicle involvement, and margin involvement were
all predictive [59]. The same group later studied serum
levels of caveolin 1. As noted above, in a study [21] of 119
radical prostatectomy patients on multivariate analysis only
caveolin 1 staining and SV involvement were predictive on
multivariate analysis, but bcl-2, p53, Ki-67, PSA, Gleason
score, Capsular penetration, age, and margin positivity were
not. Forcaveolin1 positive patients, 9/32 (28%)failed versus
7/87 (8%) that were negative. In 232 prostatectomy patients
that included lymph node positive and those that received
salvage radiation therapy [60], with a median followup of 70
months, the 5-year biochemical-free survival rate was 80%.
On multivariate analysis, only Gleason sum (not Caveolin 1
staining) was a signiﬁcant predictor of failure. When limited
to lower risk patients (n = 177) with exclusion of lymph
node positive, seminal vesicle positive, Gleason > 7, and
extracapsular extension/margin positive, caveolin 1 was still
not a signiﬁcant predictor on multivariate analysis. They did
ﬁnd that in evaluating only the recurring patients, those that
had caveolin 1 over expression did worse. In a similar study
[61], 30% of 152 radical prostatectomy patients (including
lymph node positive) stained positive for caveolin 1. It
was not predictive on multivariate analysis (only seminal
vesiclepositivity, margin positivity, and PSAwere), butwhen
restricted to patients with organ-conﬁned disease, it was the
lone predictive factor. This is somewhat in contradistinction
to the low risk patients noted in the study above.
3.19. Zinc-Alpha2-Glycoprotein (AZGP1). Zinc-alpha2-gly-
coprotein (AZGP1) encodes for a protein historically
thought to be involved in lipolysis and thought to have a
role in the cachexia of cancer. From a series of 732 radical
prostatectomy patients [62], 228 were analyzed. Forty-three
percent failed with a PSA rise of ≥0.2ng/mL. On IHC, tissue
was scored as absent or weak versus strong AZGP1 staining.
Twenty-nine percent stained weak. Although there were few
events, it appears to be predictive of clinical recurrence
and distant metastasis, but there was no evaluation as
t om o d i ﬁ c a t i o no fc o m m o np r o g n o s t i cf a c t o r s .I nag e n e
array study [63] discussed below, AZGP1 was predictive for
nonrecurrence.
3.20. Alpha Methylacyl CoA Racemase (AMACR). Alpha
methylacyl CoA racemase (AMACR) is a catalytic enzyme
(of fatty acids) that is frequently over expressed in prostate
cancer, but levels are decreased in advanced cancers as
compared to localized. In 204 radical prostatectomy patients
[64], IHC was performed for AMACR expression proteins
and regression analysis was used to correlate staining with
PSA failure (>0.2ng/mL). With visual scoring on a scale of
1–4, there was no correlation with failure, but with quanti-
tative expression analysis, patients in the lower tertile were
more likely to recur. For patients more than 1.11 standard
deviations below the cut point, 37.5% failed versus 14.5% if
theywere above.This was signiﬁcant onmultivariate analysis
along with PSA, Gleason score, and margin status, but there
was no evaluation as to the actual eﬀect on the prognostic
ability of those factors.
3.21.GeneArraysandPanels. Withtheuseofgeneexpression
micro arrays, the hope is that by screening a large number of
genes, genes highly predictive of cancer recurrence could be
identiﬁed. When using probe arrays, multiple genes can be
identiﬁed that may predict for relapse. Several groups have
evaluated this approach in predicting failure postprostate-
ctomy. In a gene expression proﬁle of 225 tumors with a
medianfollowupof8years[63],itwas foundthatMUC1was
predictive of recurrence and AZGP1 was predictive of nonre-
currence. Bothof these geneswere predictive onmultivariate
analysis alongwithGleasonscore,stage,andPSA.Therewere
no actual outcome results given. A similar study [28] of 259
RRP patients with a median followup of 57 months searched
also for markers using microarray assay. They found that the
combination of EZH2 increased and ECAD decreased was
most predictive of 5-year recurrence (38% versus 15% for
those without that combination). On multivariate analysis,
this ratio was signiﬁcant along with PSA, margin status,
and pathological stage, but not Gleason score. For organ-
conﬁned patients that were margin negative, those that were
EZH2/ECAD elevated had a 27% recurrence rate, versus
10% for those that had a decreased ratio. They did not
report on higher-risk patients. In a diﬀerent study of 100
lymph node negative prostatectomy patients [65], with a
median followup of 70 months an expression analysis of
12,625 transcripts identiﬁed 218 genes that were either up-
or down regulated. Recurrence was deﬁned as three rising
PSA levels. The combination that predicted recurrence was
deemed “poor markers”. For Gleason 6-7 cancers, the 5-year
disease-free survival was 69%, but was 77% in the good
markergroupand47%inthepoormarkergroup.InGleason
8-9cancers,the5-yeardisease-free survivalratewas26%,but
was 67% with good markers and 0 with poor markers. On
multivariate analysis, Gleason score and the gene expression
markers were predictive of recurrence, but PSA and age were
not. Using a postoperative nomogram [66]t h e yi d e n t i ﬁ e d
poor risk patients by nomogram (undeﬁned) who had a
28% 5-year disease-free survival, increasing 50% with good
genemarkers, but19%with poormarkers. Inthenomogram
predicted favorable group, 5-year disease-free survival was
81%, which was 87% with good markers and 59% with poor
markers. The major limitation of the study is that there were
only 21 patients in the training set and 79 patients in the
validation set.
Another approach is to pool multiple genes in order to
try to produce a more powerful predictive model. This has
been successful in breast cancer [67, 68]. With that approach
[69], using a 70 gene set in it was possible to predict12 Prostate Cancer
27/29 “aggressive” and 27/32 “nonaggressive” cancers and
predicted 16 of the 18 failures. Unfortunately, it appears
only 61 patients were evaluated; there was no indication of
how the ﬁndings related to standard prognostic factors. In
a more comprehensive study [70] of 639 patients selected
for systemic recurrence, biochemical (PSA) recurrence and
nonrecurrence at 7 years, the groups were evaluated for
genes that diﬀered between them. Patients with adjuvant
treatment were not excluded and failure was with a PSA >
0.2 and rising. The patients were divided into training and a
validation set. Ultimately, a 17-gene panel was determined
to be predictive. Clinical models based on Gleason score,
and pathological stage (PSA and age were not informative)
demonstrated a correlation (area under the curve) of
0.76 (0.74–0.78), while the probe set was 0.85 and the
combination of the two was 0.87. They reported that the
AUC for the validation set was lower. They compared their
results to those of other gene array studies and found that
all the other models performed better than the clinical
model alone (0.74, ranging from 0.76–0.86), with their
1 7g e n ep r o b eb e i n gt h eh i g h e s t .A l lt h ev a l i d a t i o ns e t s
were lower than the training sets for these genes. In an
exploratory study [71] of 72 prostatectomy patients with
a median followup of 28 months, 24% relapsed. After
scanning for 59,619 probe sets, over 200 genes could be
identiﬁed that are associated either positively with relapse.
In another exploratory study [72], tissue from 37 failing
patients and 42 nonfailing patients was tested with a
22,283-gene probe microarray. The ﬁrst goal was to see
if the identiﬁed genes (ultimately 5–8 were used) could
correctly identify the failing versus the nonfailing patients,
which it did 75% of the time. When combined into a
nomogram, the predictive rate increased to 89%. Given
that nomograms are the most robust incorporation of
the standard prognostic factors; this would represent an
example of how molecular data can increase the ultimate
ability to predict who will fail. Unfortunately, the number
of patients evaluated was very small, so any conclusions are
tentative at best. One last study took a diﬀerent approach.
Rather than do a blind probe for over- or under expressed
genes, they [73] evaluated a pre-existing class of predictive
genes like those successful in breast cancer [74]. Although
the actual genes are variable, most of the predictive breast
cancer genes fall under the general classiﬁcation of cell cycle
progression genes. In evaluation of that class of genes in a
large prostatectomy cohort [73] (442 with tissue, median
followup 9.5 years), a panel of 31 was tested for their ability
to predict recurrence. Overall, 10-year progression-free
survival was 64%. When evaluated for the standard ﬁndings
of PSA, Gleason score, and pathologic ﬁndings, the patients
could be divided into two groups based on these clinical
factors. The low-risk group were patients with Gleason <
7, organ-conﬁned disease, and PSA < 10ng/mL (actually,
PSA up to 30ng/mL did not change the risk). Their 10-year
risk of biochemical failure (PSA > 0.1ng/mL) was 17%,
but for those with a low CCP score, it was 4% and for a
high CCP score it was 24%. For clinical high-risk patients
(Gleason ≥ 7 and/or nonorgan conﬁned and/or PSA > 30),
10-year biochemical failure was 61%, which was 51% for
low CCP score, and 64% for high score. On multivariate
analysis, they the CCP score was predictive of recurrence.
It is interesting to note, as pointed out previously [71],
using multigene predictive models, there is little overlap in
the genes that are found to be signiﬁcant in each of the
models. This is postulated to be a factor of a large number
of genes and a high signal-to-noise ratio associated with the
prediction of biochemical recurrence. The challenge then is
to determine which of these are true prognostic markers and
which are otherwise just testing anomalies. It will take large
comprehensive studies to determine this.
4.Conclusion
This paper covered those tissue markers that have been
evaluated as prognostic factors in radical prostatectomy
patients. These markers and multiple others have also
been evaluated in patients with noncurative treatment
and metastatic disease, as well as numerous tissue culture
systems. There are undoubtedly many useful makers that
will be identiﬁed, especially with the high volume analyses
possible with the microarrays. At this time, none of them
have been overwhelming in their prognostic ability nor do
they have a value that mandates clinical use.
The reason for the failure of molecular markers in con-
sistently predicting outcomemay partially be dueto the vari-
ability between studies due to their methodological diﬀer-
ences. Unfortunately, most studies are too small to compre-
hensively evaluate their ability to improve on the prognostic
ability of the standard factors of PSA, Gleason score, and
stage. Until that occurs, they will remain research curiosities.
In terms of the pathway forward for a useful marker
or signature in prostate cancer, we have many challenges.
Our current classiﬁcation of prostate cancer even at the very
rudimentary molecular level is lacking. The estrogen, pro-
gesterone, and Her 2-neu receptor status of breast cancer has
allowed stratiﬁcation of a complex disease for clinical trials
and as a paradigm for molecular signature generation. To
date, this has not been possible in prostate cancer, although
recent work suggests the imprinting of the TMPRSS2-ERG,
PTEN, and androgen receptor conﬁgurational status may be
suitable. Similarly, basic molecular predictors of outcome in
the adjuvant, hormone-na¨ ıve, and castrate-resistant settings
have been slow to develop in a disease that in its most
aggressive form evolves over a decade. Finally, predictors
of response to standard therapies have been diﬃcult to
characterize in the absence of a single dominant gene or the
ability to subsegment the disease. To move forward, markers
or gene signatures will need to have strong biological base,
be linked to a therapeutic intervention and have enough
strength to add to the formidable triad of stage, Gleason
score, and serum PSA in prostate cancer.
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